Investigation Casts Doubt Over Trial Used To Support Top-selling Anti-clotting Drug
An investigation published by The BMJ today raises new concerns about the top-selling anti-clotting drug, rivaroxaban (Xarelto).
It questions the validity of a pivotal trial - known as the ROCKET-AF…